2
Specific identification of chronic lung disease in premature babies
mehr
Asklepios Kliniken GmbH & Co. KGaA
Ingelheim, Germany (ots/PRNewswire) - - For non-US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented Monotherapy treatment with the triple angiokinase inhibitor(1) BIBF 1120 (planned tradename ...